Director Frank E. Jaumot of Nutex Health Inc. (NASDAQ:NUTX) bought 150 shares of the company’s common stock on March 20, 2026. The shares were acquired at a per-share price of $93.555, bringing the total value of the insider purchase to $14,033.
At the time of reporting, NUTX is trading at $92.66. The stock is down 46% year-to-date while still showing a 53% increase over the past 12 months. According to InvestingPro analysis, the security is listed among opportunities classified as Most Undervalued on the platform. The InvestingPro service also notes the availability of 10 additional InvestingPro Tips for investors seeking more detailed evaluation of NUTX’s investment profile.
Separately, Nutex Health announced a 41.1% decline in revenue for the fourth quarter of 2025 compared with the same quarter in the prior year. This substantial quarterly downturn contrasts with what the company has described as a strong overall performance for the full fiscal year. The marked drop in quarterly revenue has prompted investor concern and increased attention from analysts, who are monitoring the company’s results closely.
There have been no recent analyst upgrades or downgrades reported for Nutex Health. The financial results and the company’s trajectory have been the subject of discussion among market participants, focusing on Nutex Health’s strategic direction and operational efficiency. Nutex Health’s management has not issued a public response addressing these concerns.
The insider purchase by a board director, occurring in the context of mixed financial signals, is an observable data point for market observers. While the transaction is modest in dollar terms, it is recorded alongside ongoing investor scrutiny following the quarterly revenue decline.
Summary
Director Frank E. Jaumot purchased 150 shares of Nutex Health at $93.555 per share on March 20, 2026, for $14,033. The purchase comes as NUTX trades at $92.66, down 46% year-to-date but up 53% over the past year. The company reported a 41.1% drop in fourth-quarter 2025 revenue year-over-year, and no recent analyst rating changes have been disclosed. InvestingPro lists the stock among its Most Undervalued picks and offers additional tips for interested investors.